New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
16:07 EDTADMSAdamas Pharmaceuticals initiates Phase 3 trial for ADS-5102
Adamas Pharmaceuticals announced that it has initiated a pivotal Phase 3 clinical study of ADS-5102, a high-dose, controlled-release version of amantadine for the treatment of patients with Parkinson's disease who have developed levodopa-induced dyskinesia. LID is a condition characterized by involuntary movements without purpose that can become severely disabling, rendering individuals with Parkinson's disease unable to perform routine daily tasks. The Phase 3 study will enroll approximately 130 patients. It is a 26-week multi-center, randomized, double-blind, placebo-controlled trial, which will assess the efficacy of a once daily 340 mg dose of ADS-5102 administered at bedtime for the treatment of LID in individuals with Parkinson's disease. The primary endpoint of EASE LID is a reduction in LID as assessed by changes in the Unified Dyskinesia Rating Scale along with supporting data from secondary endpoints.
News For ADMS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 28, 2014
16:07 EDTADMSAdamas Pharmaceuticals expands ADS-5102 Phase 3 program
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use